Previous close | 11.50 |
Open | 11.77 |
Bid | 11.76 x 1100 |
Ask | 11.80 x 1800 |
Day's range | 11.34 - 11.88 |
52-week range | 4.34 - 18.40 |
Volume | |
Avg. volume | 11,890,640 |
Market cap | 942.467M |
Beta (5Y monthly) | -0.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.35 |
Earnings date | 11 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 28 Apr 2014 |
1y target est | 34.00 |
A couple of stocks that are doing exceptionally well this year are Veru (NASDAQ: VERU) and Chevron (NYSE: CVX). Pharmaceutical company Veru has been among the hottest stocks to own this year, having more than doubled in value while the S&P 500 is firmly in negative territory, down 13%. The company and its investors are hoping that the Food and Drug Administration (FDA) grants it Emergency Use Authorization (EUA) as phase 3 trials have shown it is effective in reducing the risk of death among hospitalized patients.
Envista (NVST) delivered earnings and revenue surprises of 4.35% and 1.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
In the latest trading session, Veru Inc. (VERU) closed at $12.10, marking a -0.9% move from the previous day.